www.bionomics.com.au
Bionomics is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system. Through application of its proprietary technology platforms, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy.
Bionomics' anti anxiety compound BNC210 Phase 1 trial is successful
Drug discovery and development company Bionomics (ASX: BNO) has continued the spate of good news with its anti-anxiety drug compound BNC210 and second Phase 1 clinical trial results, that have successfully established a four-fold increase in blood drug levels following food intake.
The objective was to determine whether administration of BNC210 with food alters blood levels of the drug. The results expand the dosing range to be used in treatment of of anxiety and depression, establishing a safety profile for the compound, with no significant side effects from useage.
Dr Deborah Rathjen Bionomics’ CEO & managing director explained that “many common drugs are taken either with food or following a meal. The increased exposure seen when BNC210 is given with food expands the potential dosing range to be used in its continued development for the treatment of anxiety and depression".
Rathjen said "it has allowed us to identify the doses to be used in the planned Phase Ib studies of BNC210. The data also suggests that lower doses of BNC210 may be effective when the drug is given with food”.
“This latest data also confirms the results of the initial Phase I clinical trial of BNC210 which indicated that BNC210 was well tolerated at high doses and free of significant side-effects”, she added.
The placebo controlled and blinded trial was conducted in healthy male volunteers at the Pain and Anaesthesia Research Clinic (PARC) within the Royal Adelaide Hospital and Professor Paul Rolan was the Principal Investigator.
Among the secondary objectives of this trial is the evaluation of potential biomarkers showing BNC210 effects. These include the determination of stress hormone levels.
These tests are currently in progress with data anticipated to be available next quarter.
Two Phase Ib clinical trials of BNC210 are anticipated to commence next quarter. The first of the new trials will evaluate BNC210 effects when anxiety is induced in healthy subjects whilst the second trial will evaluate BNC210 effects on the brain using electroencephalograph (EEG) measurements. The trials will continue to look at whether side effects such as sedation or memory impairment, are associated with the administration of BNC210.
